Holen Sie sich die Stockscreener-App
18.87
6.03%
-1.21
Vorhandelsmarkt:
19.20
0.33
+1.75%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces safety hurdles - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences - MarketBeat
Sarepta Therapeutics (SRPT): Mizuho Lowers Price Target to $40 | SRPT Stock News - GuruFocus
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls - Yahoo Finance
Sarepta (SRPT) Faces Price Target Cut Amid Liver Failure Concerns | SRPT Stock News - GuruFocus
TD Cowen downgrades Sarepta Therapeutics to 'hold' - TradingView
Sarepta stock plunges 42% after second fatal liver failure case - Investing.com
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics - BioSpace
Sarepta (SRPT) Downgraded to Hold with Revised Price Target | SRPT Stock News - GuruFocus
Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research… - MarketScreener
Sarepta stock downgraded by TD Cowen on Elevidys approval concerns - Investing.com
Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys - Investing.com
Sarepta Therapeutics (SRPT) Price Target Lowered by Deutsche Ban - GuruFocus
Sarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys Setback - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys - CGTLive®
Sarepta Therapeutics price target lowered to $28 on safety concerns - Investing.com
Sarepta Therapeutics price target lowered to $28 on safety concerns By Investing.com - Investing.com UK
Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI - StreetInsider
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm | FinancialContent - FinancialContent
Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation - simplywall.st
Sarepta Therapeutics (SRPT) Downgraded by Goldman Sachs to Neutral | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Downgraded by Morgan Stanley | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Slashed by Baird | SRPT Stock News - GuruFocus
From $172 to $20: Sarepta’s Spectacular Fall - Trefis
Sarepta Reports Second Death of Patient Using Its Gene Therapy - MSN
Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles By Investing.com - Investing.com South Africa
Lilly adds highest Zepbound doses to DTC offering - statnews.com
Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | S - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | SRPT Stock News - GuruFocus
Pharmalittle: We're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more - statnews.com
Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles - Investing.com India
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law - Business Wire
SRPT Stock: What’s Happening With Sarepta Therapeutics? - Forbes
Sarepta Therapeutics (SRPT): Analyst Lowers Price Target Amid In - GuruFocus
Sarepta (SRPT) Price Target Slashed, Uncertainty Surrounds Future | SRPT Stock News - GuruFocus
Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Ami - GuruFocus
Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Amid Safety Concerns | SRPT Stock News - GuruFocus
This Week’s CGT News: Investigating the Long-Term Safety of Gene Therapy for Hemophilia B - themedicinemaker.com
2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy - MSN
Biotech pauses trial after second patient death linked to gene therapy - The Washington Post
Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug - MSN
Sarepta (SRPT) Faces Price Target Cut Amid Gene Therapy Concerns - GuruFocus
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent
Elevidys’ second liver death hits Sarepta, sends DMD ripples - BioWorld MedTech
Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death - insights.citeline.com
Sarepta shares crash as second patient dies after receiving its gene therapy - MSN
Health Care Down as Sarepta Slides -- Health Care Roundup - MarketScreener
Second patient death reported with gene therapy for muscular dystrophy - Hazleton Standard Speaker
Second Teenage Boy Dies From Liver Failure After Sarepta Gene Therapy Treatment - Bloomberg
Wolfe Research Begins Coverage of Sarepta (SRPT) with Neutral Rating | SRPT Stock News - GuruFocus
Sarepta Therapeutics Stock Drops 44.4% Amid Elevidys Gene Therapy ConcernsNews and Statistics - IndexBox
Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies - Investor's Business Daily
These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's
Sarepta's Shares Plummet After Duchenne Treatment Halt - Finimize
AMD pops, Sarepta tanks, EchoStar & Trump: Trending Tickers - Yahoo Finance
Sarepta Therapeutics (SRPT) Sees Target Price Adjustment by Jeff - GuruFocus
Sarepta stock rating cut by Morgan Stanley on patient safety concerns - Investing.com
After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry - statnews.com
2.27%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):